Navigation Links
Bell Ventures Launches Breakthrough Radical Defense Skin Care Ingredient
Date:12/8/2008

BOSTON, Dec. 8 /PRNewswire/ -- Bell Ventures LLC, a leader in innovative antioxidant solutions in food, nutrition, and skin care, announces the release of its new, high-performance natural ingredient, GlobalPAX(TM).

GlobalPAX(TM) is a proprietary extract made from the world's finest natural sources of proanthocyanidins (PACs), a powerful class of antioxidants. It is the first high-performance ingredient to standardize antioxidant capacity to Total ORAC, which analyzes antioxidant protection against 5 free radicals.

Bell Ventures also uses recognized markers of skin damage to demonstrate efficacy. GlobalPAX(TM) is standardized to collagenase and elastase inhibition, evidence that it helps defend against skin damage.

David Bell, President of Bell Ventures, says, "GlobalPAX(TM) is the result of our deep understanding of the science of antioxidants and our appreciation for their benefits to the skin. PACs are a very versatile antioxidant family, and we see this in the protection GlobalPAX(TM) delivers."

GlobalPAX(TM) provides powerful broad-spectrum defense against hydroxyl, peroxyl, peroxynitrite, singlet oxygen, and superoxide anion. Each of these radicals is implicated in skin damage.

The premium anti-aging skin care market is hungry for novel, high-performance naturals. The benefits of antioxidant protection provided by GlobalPAX(TM) make it ideal for differentiating next-generation products.

GlobalPAX(TM) has already received the attention of significant players in the industry. "We outperform a wide range of popular antioxidant ingredients, such as vitamin C, green tea extract, and green coffee cherry extract," Bell reports.

GlobalPAX(TM) can also be used to differentiate dietary supplements and the emerging category of inside-out skin care products and "beauty foods."

With standardized Total ORAC greater than 25,000 per gram, PACs, and skin outcome markers, GlobalPAX(TM) differentiates itself in a crowded market. As Bell says, "GlobalPAX(TM) lives up to its slogan, Prove what goes in before it goes on."

For more information call: 508-536-9511, email globalpax@bellventures.com, or visit http://www.globalpax.net


'/>"/>
SOURCE Bell Ventures LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
2. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
3. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
4. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
5. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
6. Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Clarus Ventures Closes $660 Million Fund
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):